- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02791204
SPECT/CT Imaging of Skeletal Muscle Perfusion
SPECT/CT Imaging of Skeletal Muscle Perfusion in Healthy Control Subjects and Patients With Peripheral Arterial Disease: Pilot Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Peripheral arterial disease (PAD) is a progressive atherosclerotic disease of the lower limbs that affects 8 to 10 million Americans, and is more prevalent and progresses more quickly in patients with diabetes mellitus (DM). There is a critical need for a standard non-invasive approach to assess response to treatment by three-dimensional (3D) perfusion to vascular territories of the feet in PAD patients. Assessing the response to treatment is particularly important in DM patients, who suffer from poor distal runoff and often require more distal revascularization to achieve limb salvage.
In this clinical study, the investigators will evaluate lower extremity skeletal muscle perfusion in the feet of healthy controls and PAD patients who are undergoing revascularization using conventional sodium iodide SPECT/CT imaging, as well as dynamic SPECT/CT imaging with a unique cadmium zinc telluride (CZT) system.
Healthy control subjects will be recruited from Yale University and the greater New Haven area. In addition to healthy control subjects, 35 PAD patients with previously diagnosed diabetes will be recruited from Vascular Surgery and Interventional Cardiology at Yale-New Haven Hospital. Patients who are undergoing revascularization procedures will be identified and asked to participate in the imaging study prior to their revascularization procedure and will be imaged once again 1-3 days following revascularization, prior to hospital discharge.
Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. They will be injected with a low dose radiotracer. In healthy control subjects, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes. Additionally, we will sample heated venous "arterialized" blood from a hand vein retrograde to evaluate the potential for heated venous blood in the calculation of a blood input function, thus eliminating the need for arterial access in future PAD patient studies.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Albert J. Sinusas, MD
- Phone Number: 203-785-5005
- Email: albert.sinusas@yale.edu
Study Contact Backup
- Name: Donna McMahon
- Phone Number: 203-785-5005
- Email: donna.mcmahon@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale-New Haven Hospital
-
Contact:
- Albert J Sinusas, MD
- Phone Number: 203-785-5005
- Email: albert.sinusas@yale.edu
-
Contact:
- Donna McMahon
- Email: donna.mcmahon@yale.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
- healthy control subjects will be enrolled for this study.
- PAD patients with diabetes who are undergoing revascularization procedures
- patients undergoing clinically indicated myocardial perfusion imaging study
Description
Inclusion Criteria for Healthy Control Population:
- At least 18 years of age
- Normal (0.9-1.2) Ankle Brachial Index
Inclusion Criteria for patients undergoing clinically indicated myocardial perfusion study:
1) At least 18 years of age 2) scheduled for stress myocardial perfusion imaging study for clinically indicated reason
-Inclusion Criteria for PAD Patient Population:
- At least 18 years of age
- Evidence of significant obstructive disease for one or multiple lower extremity arteries, as identified by CT angiography, ultrasound, or MR imaging or an abnormal ankle-brachial index or toe-brachial index
- Previously diagnosed diabetes mellitus (type I or II), based on any of the following criteria: fasting plasma glucose great than 126 mg/dl on 2 separate occasions, glycated hemoglobin (HbA1c) greater than 6.5% on 2 separate occasions, fasting plasma glucose greater than 200 mg/dl 2 hours following an oral glucose tolerance test on 2 separate occasions, or fasting plasma glucose and HbA1c above normal limits on same visit.
- scheduled for revascularization due to obstructive blood flow in the lower extremities.
Exclusion Criteria for Healthy Control Population:
- Unable to give informed consent
- Enrolled in another trial
- Preexisting medical conditions affecting the vascular system including, but not limited to: Coronary Artery Disease, Peripheral Arterial Disease, diabetes, cancer, hypertension, history of smoking
- Pregnant or nursing
Exclusion Criteria for PAD Patient Population:
- Unable to give informed consent or follow-up
- Enrolled in another trial
Exclusion Criteria for patients undergoing clinically indicated myocardial perfusion study:
1) Unable to give informed consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants with PAD
Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems.
Subjects will be injected with a low dose radioisotope.
Heated venous blood sampling will be obtained.
|
Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems.
Subjects will be injected with a low dose radioisotope.
Heated venous blood sampling will be obtained.
|
Controls
Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems.
Subjects will be injected with a low dose radioisotope.
In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
|
Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems.
Subjects will be injected with a low dose radioisotope.
In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment of effect of percutaneous revascularization treatment measured by change in lower extremity skeletal muscle perfusion before and after treatment using quantitative SPECT/CT imaging of the lower extremities.
Time Frame: patients will be assessed prior to the revascularization procedure (baseline) and a second time 1-3 days following revascularization.
|
patients will be assessed prior to the revascularization procedure (baseline) and a second time 1-3 days following revascularization.
|
Assessment of lower extremity skeletal muscle perfusion in healthy control subjects compared to patients with peripheral arterial disease and diabetes using quantitative SPECT/CT imaging.
Time Frame: baseline
|
baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Albert J. Sinusas, MD, Yale University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1603017342
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on SPECT/CT imaging following revascularization procedures
-
University of California, San FranciscoCompletedFeasibility of Using SPECT/CT Imaging to Map Lymphatic Drainage Patterns in Prostate Cancer PatientsProstate CancerUnited States
-
Nationwide Children's HospitalOhio State UniversityRecruitingDiabetes Mellitus | Peripheral Artery Disease | Chronic Limb-Threatening IschemiaUnited States
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaTerminated
-
University of MichiganNational Institutes of Health (NIH)CompletedNon-Hodgkin's LymphomaUnited States
-
University Health Network, TorontoAytu BioPharma, Inc.; Hybridyne Imaging Technologies IncCompleted
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingChronic Obstructive Pulmonary Disease (COPD)United States
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruiting
-
Baptist Health South FloridaGE HealthcareCompleted
-
Ottawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR); The Finnish Funding Agency for...CompletedCoronary Artery Disease | Heart Failure | Ischemic CardiomyopathyCanada, Finland, United States, Argentina, Brazil
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruiting